All In MedTech

FDA Clearance Tracker · P990004-S073

SURGIFLO™ Hemostatic Matrix Kit with Thrombin

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 9, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 9, 2025

Approved

Time to decision

90 days

Received Apr 10, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P990004-S073
Device name
SURGIFLO™ Hemostatic Matrix Kit with Thrombin
Applicant location
Soeborg
Received
Apr 10, 2025
Decided
Jul 9, 2025
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P990004

Device type

Device class
Class III
Regulation
21 CFR 878.4490

Every decision under product code LMF

FDA's approval statement

As written in FDA's record.

Approval for a line extension of SURGIFLO™ Hemostatic Matrix Kit with Thrombin

Source documents

Other decisions for Ferrosan Meidcal Devices A/S

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.